This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.

NCT01250951 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

111

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndrome
Thalassemia

Interventions

DRUG: Deferasirox

Sponsor

Novartis Pharmaceuticals